CDN1163 is an allosteric activator of sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis in a genetic model of insulin resistance and type 2 diabetes (ob/ob mice). CDN1163 treatment significantly reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis. Moreover, CDN1163 increased ER calcium content, rescued neurons from ER stress-induced cell death in vitro, and showed significant efficacy in the rat 6-hydroxydopamine (6-OHDA) model of Parkinson's disease.

KEYWORDS: CDN1163 | supplier | SERCA activator | CDN 1163 | CDN-1163 | CAS [892711-75-0] | ATP | ATPase (Ca2+) | Activator | Enzymes | SERCA | 6-OHDA | Obesitas | Diabetes | Metabolic Disorder | Metabolic Dysfunction | ER Stress | Parkinson's Disease